Brief: Avenue Therapeutics Says Nasdaq Halted Trading Of Company's Common Stock
15/02/2022 13:27
Feb 15 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS INC - NASDAQ HAS HALTED TRADING OF
COMPANY'S
COMMON STOCK
* AVENUE THERAPEUTICS - FDA'S ANESTHETIC & ANALGESIC DRUG
PRODUCTS
ADCOMM & DRUG SAFETY & RISK MANAGEMENT ADCOMM TO REVIEW CO'S
NDA FOR IV TRAMADOL
* AVENUE THERAPEUTICS - ADVISORY COMMITTEE MEETING IS
SCHEDULED
FOR FEBRUARY 15, 2022
Source text for Eikon: ID:nGNX46ybhZ
Further company coverage: ATXI.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Avenue Therapeutics
See all newsBrief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary